Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
Immunic (IMUX) said Tuesday it has appointed Jason Tardio as chief operating officer and president, starting July 12.Tardio most recently served as chief operating officer at Ovid Therapeutics (OVID),
Express News | Immunic- Jason Tardio Will Be Joining Co as Chief Operating Officer & President Effective July 12 2024
Express News | Immunic Appoints Jason Tardio as Chief Operating Officer and President
Immunic Appoints Ex Novartis and Biogen Exec as New COO to Lead Vidofludimus Calcium Launch | NASDAQ:IMUX
Immunic Stock (IMUX): Understanding the Current Status and Future Path for IMU-838
Express News | Immunic-Files Prospectus Supplement for Sale $80.0 Mln of Shares of Common Stock, May Offer & Sell From Time to Time Through Leerink Partners
Express News | Immunic Inc -Had Previously Entered Into Sales Agreement With Leerink Partners Dated May 2, 2022 Relating to Shares of Common Stock
When Will Immunic, Inc. (NASDAQ:IMUX) Breakeven?
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day | NASDAQ:IMUX
Immunic to Participate in Industry and Scientific Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...
Express News | Immunic Inc Raises Size of Mixed Shelf Offering to $412.3 Mln From $250 Mln - SEC Filing
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Immunic | 10-Q: Quarterly report
Express News | Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic: Q1 Earnings Snapshot
Express News | Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Express News | Immunic Inc - Expects to Be Able to Fund Its Operations Into Q3 of 2025.
Express News | Immunic Q1 Operating Expenses USD 23.881 Million
Express News | Immunic Q1 Income From Operations USD -23.881 Million